Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$54.00 – $71.00
41% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.3M | $105.6M | $336.0M | $600.6M | $956.3M | $1.72B | $1.87B | $2.27B |
| Cost of revenue | $6.8M | $23.3M | $35.3M | $85.4M | $103.3M | $122.3M | $129.5M | $156.1M |
| Gross profit | $42.5M | $82.3M | $300.7M | $515.2M | $853.1M | $1.59B | $1.74B | $2.11B |
| Gross margin | 86.2% | 77.9% | 89.5% | 85.8% | 89.2% | 92.9% | 93.1% | 93.1% |
| R&D | $207.7M | $249.2M | $238.7M | $388.7M | $473.8M | $637.7M | $683.6M | $516.9M |
| Operating income | −$287.2M | −$360.0M | −$205.2M | −$110.6M | $72.0M | $525.9M | $469.2M | $873.9M |
| EBITDA | −$282.6M | −$353.0M | −$196.6M | −$97.7M | $87.3M | $564.6M | $568.2M | $963.9M |
| Net income | −$234.7M | −$289.9M | −$167.3M | −$90.4M | $55.6M | $431.4M | $428.4M | $735.6M |
| Net margin | -475.8% | -274.5% | -49.8% | -15.1% | 5.8% | 25.1% | 22.9% | 32.5% |
| EPS (diluted) | -5.58 | -6.23 | -3.18 | -1.66 | 1.01 | 7.50 | 7.20 | 12.26 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.7B | $13.68 | $11.12–$18.46 | 1 |
| 2027 | $3.7B | $23.18 | $18.83–$31.26 | 1 |
| 2028 | $5.6B | $40.71 | $33.09–$54.92 | 1 |
| 2029 | $8.0B | $55.14 | $44.82–$74.38 | 1 |
Forward consensus · source: Financial Modeling Prep
CAMURUS AB
No one on the platform currently holds CAMRF.
No tracked institution reports a position in CAMRF as of their last filing.
No one on the platform has traded CAMRF yet.
| $3.5B |
| — |
| INCPFInnoCare Pharma Limited | $1.55 | +0.00% | $2.3B | — |
| LABFFLaboratorios Farmaceuticos Rovi, S.A. | $90.61 | +0.00% | $4.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.8× sales vs its 1.7× historical median P/S.
Fair value ≈ $57.70 · price $61.01 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.